fasudil has been researched along with Coronary Stenosis in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The coronary diameter at the concentric stenotic site, which is considered to reflect the whole circumferential atherosclerosis, in patients with stable angina pectoris (SAP; n=11) and the control site in patients with SAP and chest pain syndrome (CPS; n=9), was measured at baseline and after the intracoronary administration of nitroglycerin (200 microg) and the subsequent intravenous infusion of fasudil (30 mg for 30 min), a Rho-kinase inhibitor, during coronary angiography." | 9.12 | Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. ( Atarashi, H; Ibuki, C; Ishii, K; Kishida, H; Kodani, E; Otsuka, T; Suzuki, T; Takano, T, 2006) |
| "The coronary diameter at the concentric stenotic site, which is considered to reflect the whole circumferential atherosclerosis, in patients with stable angina pectoris (SAP; n=11) and the control site in patients with SAP and chest pain syndrome (CPS; n=9), was measured at baseline and after the intracoronary administration of nitroglycerin (200 microg) and the subsequent intravenous infusion of fasudil (30 mg for 30 min), a Rho-kinase inhibitor, during coronary angiography." | 5.12 | Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. ( Atarashi, H; Ibuki, C; Ishii, K; Kishida, H; Kodani, E; Otsuka, T; Suzuki, T; Takano, T, 2006) |
| "Epicardial coronary stenosis causes myocardial ischemia; however, the role of coronary microvessels is poorly understood in the pathogenesis of effort angina." | 2.73 | Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. ( Fukumoto, Y; Hirakawa, Y; Hirooka, Y; Inokuchi, K; Ito, A; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumoto, Y | 1 |
| Uwatoku, T | 1 |
| Oi, K | 1 |
| Abe, K | 1 |
| Hattori, T | 1 |
| Morishige, K | 1 |
| Eto, Y | 1 |
| Fukumoto, Y | 2 |
| Nakamura, K | 1 |
| Shibata, Y | 1 |
| Matsuda, T | 1 |
| Takeshita, A | 2 |
| Shimokawa, H | 3 |
| Otsuka, T | 1 |
| Ibuki, C | 1 |
| Suzuki, T | 1 |
| Ishii, K | 1 |
| Kodani, E | 1 |
| Atarashi, H | 1 |
| Kishida, H | 1 |
| Takano, T | 1 |
| Mohri, M | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Hirakawa, Y | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Utsunomiya, T | 1 |
| Satoh, S | 1 |
| Ikegaki, I | 1 |
| Toshima, Y | 1 |
| Asano, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fasudil and Coronary Stenosis
| Article | Year |
|---|---|
Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Angiography; Chest Pain; Coron | 2006 |
Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Co | 2007 |
2 other studies available for fasudil and Coronary Stenosis
| Article | Year |
|---|---|
Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Blood Proteins; Catheterization; | 2004 |
Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anesthesia; Angina Pectoris; Animals; Cardiac Pacing, | 2001 |